14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MBGL vs MFP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, MBGL (MBGL) is the stronger overall head-to-head candidate over MFP (MFP) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). MBGL carries a Unified Composite Score of 39.2/100 (SELL) at $22.63 (N/M Forward P/E, N/A operating margin), whereas MFP carries 38.7/100 (SELL) at $44.19 (N/M Forward P/E, N/A operating margin).
Defensive Composite Rating Caution: Although MBGL compares more favorably head-to-head, both MBGL (39.2/100 SELL) and MFP (38.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBGL vs MFP. Trailing 12-month operating profitability (MBGL N/A vs MFP N/A) and valuation multiples (MBGL N/M vs MFP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MBGL vs MFP Key Questions & Quantitative Answers
As of Nov 20, 2026, MBGL (MBGL) is the stronger overall head-to-head candidate over MFP (MFP) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). MBGL carries a Unified Composite Score of 39.2/100 (SELL) at $22.63 (N/M Forward P/E, N/A operating margin), whereas MFP carries 38.7/100 (SELL) at $44.19 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although MBGL compares more favorably head-to-head, both MBGL (39.2/100 SELL) and MFP (38.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
MBGL and MFP split Growth & Scale metrics: MBGL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MFP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MBGL generates N/A in USD-normalized revenue versus N/A for MFP. In operating R&D and SG&A reinvestment, MBGL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MFP.
MBGL and MFP trade at balanced relative valuation multiples. MBGL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MFP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBGL (N/A ROE) versus MFP (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, MBGL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.05β · 65% Vol realized risk). By comparison, MFP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.26β · 69% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.